{
    "General": {
        "Code": "L1PA",
        "Type": "Common Stock",
        "Name": "LEE S PHARMACEUTIC.HD-05",
        "Exchange": "F",
        "CurrencyCode": "EUR",
        "CurrencyName": "Euro",
        "CurrencySymbol": "\u20ac",
        "CountryName": "Germany",
        "CountryISO": "DE",
        "OpenFigi": null,
        "ISIN": "KYG5438W1116",
        "LEI": null,
        "PrimaryTicker": "0950.HK",
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "December",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Drug Manufacturers-Specialty & Generic",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Pharmaceuticals",
        "GicSubIndustry": "Pharmaceuticals",
        "Description": "Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 1102,
        "UpdatedAt": "2023-08-31"
    },
    "Highlights": {
        "MarketCapitalization": 91197152,
        "MarketCapitalizationMln": 91.1972,
        "EBITDA": 237898000,
        "PERatio": 14.8,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": 3.268,
        "DividendShare": 0.02,
        "DividendYield": 0.0156,
        "EarningsShare": 0.01,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": 0,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": "2022-12-31",
        "ProfitMargin": 0.0416,
        "OperatingMarginTTM": 0.1034,
        "ReturnOnAssetsTTM": 0.0248,
        "ReturnOnEquityTTM": 0.0217,
        "RevenueTTM": 1233148032,
        "RevenuePerShareTTM": 2.094,
        "QuarterlyRevenueGrowthYOY": -0.372,
        "GrossProfitTTM": 770755000,
        "DilutedEpsTTM": 0.01,
        "QuarterlyEarningsGrowthYOY": 1.472
    },
    "Valuation": {
        "TrailingPE": 14.8,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": -14354016,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 588835008,
        "SharesFloat": 224887994,
        "PercentInsiders": 63.617000000000004,
        "PercentInstitutions": 6.087,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": 0.9591,
        "52WeekHigh": 0.2221,
        "52WeekLow": 0.144,
        "50DayMA": 0.1592,
        "200DayMA": 0.1779,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0,
        "ForwardAnnualDividendYield": 0.0156,
        "PayoutRatio": 0.4707,
        "DividendDate": null,
        "ExDividendDate": "2023-05-25",
        "LastSplitFactor": null,
        "LastSplitDate": null,
        "NumberDividendsByYear": {
            "0": {
                "Year": 2019,
                "Count": 2
            },
            "1": {
                "Year": 2020,
                "Count": 2
            },
            "2": {
                "Year": 2021,
                "Count": 2
            },
            "3": {
                "Year": 2022,
                "Count": 2
            },
            "4": {
                "Year": 2023,
                "Count": 1
            }
        }
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}